Monday, May 27, 2013
BioCentury's 11th annual
European Iceberg survey sees funding demand continue to fall for a shrinking
number of public clinical-stage biotechs in Europe, while the capital demanded
by the growing cadre of venture biotechs continues to outstrip the supply.
The Iceberg survey aims to
identify the underlying demand for finance by private and public biotechnology
companies in Europe, including Israel, over the next three years of operations.
It includes only companies that have reached the clinic or the market, and
excludes discovery and preclinical plays. It also excludes profitable publicly